Safety and Feasibility Study of Controlled Blood-stage Plasmodium Vivax Malaria Infection by Injection of Cryopreserved Infected Red Blood Cells in Healthy Thai Adults
Led by University of Oxford · Updated on 2026-01-12
48
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and feasibility of a controlled human Plasmodium vivax malaria infection CHMI in healthy adult Thai volunteers. This study aims to find the best dose of cryopreserved P. vivax infected red blood cells for future studies by experimentally injecting these infected cells into volunteers. The study involves up to 48 participants, who will be closely monitored in a hospital setting, with the goal of understanding the infection process and treatment responses.
Participants will receive one of four doses of infected red blood cells, ranging from a whole vial to diluted amounts, administered by injection. Each dose will be tested in groups of volunteers to identify which dose reliably produces infection. The study includes a screening period, a challenge day for infection, a monitoring phase until treatment criteria are met, and a follow-up period lasting one year after treatment.
Volunteers will be admitted to the hospital for close monitoring, including daily health checks and blood tests to detect malaria parasites and assess immune responses. After infection is confirmed, blood samples will be taken twice daily until participants meet treatment criteria, at which point antimalarial drugs will be given. Follow-up visits will occur over the next year to monitor health, immune response, and possible parasite transmission. Safety and infection outcomes will be analyzed throughout the study period.
CONDITIONS
Brief Title
A Controlled Human Vivax Malaria Infection Study Through Inoculation of Infected Erythrocytes
Research Team
N
Nicholas Day, MD
J
Jetsumon Sattabongkot Prachumsri, Ph.D
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Immunosuppressive or immunodeficient states, including HIV or history of splenectomy
Immunosuppressant medication use within 6 months before enrollment (inhaled/topical steroids allowed)
History of allergic reactions likely worsened by malaria
Pregnancy, breastfeeding, or planning pregnancy during the study
Contraindications to antimalarial drugs used in study
Use of medications interacting with antimalarial drugs used
Positive family history of early cardiac disease
History of cardiac arrhythmia or clinically relevant bradycardia
Family history of congenital QT prolongation or sudden death
Conditions or medications known to prolong QT interval
ECG showing QTc interval ≥ 450 ms
History or suspicion of alcohol or drug abuse
Participation in another clinical study during the study period
Hemoglobin below 11 g/dL
Positive hepatitis B surface antigen or hepatitis C seropositive
Abnormal liver enzymes or kidney function tests beyond defined limits
Rhesus negative blood group
Blood incompatibility with inoculum
Positive COVID-19 test by RT-PCR
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Challenge
Duration - About 2 weeks until reaching malarial treatment criteria
Participants receive a controlled inoculation of malaria parasitized red blood cells in one of four different dose levels to assess infection development.
Daily visits starting Day 1 after challenge until malaria qPCR becomes positive, then twice daily visits until antimalarial treatment initiation
Antimalarial Treatment and Hospital Monitoring
Duration - Up to 3 weeks post-challenge depending on infection status
Participants receive antimalarial treatment once infection criteria are met and are monitored daily in the hospital until clinical recovery and parasite clearance.
Daily visits for blood tests until clinical recovery and two consecutive negative malaria blood films
Follow-up
Duration - 1 year post antimalarial treatment initiation
Participants attend outpatient visits after hospital discharge for continued monitoring of health status, malaria parasite presence, immune response, and other safety assessments.
Outpatient visits on days 7, 28, 60, 90, 180, and 1 year post-treatment
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
4
Similar Trials
Safety and Feasibility Study of Controlled Blood-stage Plasmodium Vivax Malaria Infection by Injection of Cryopreserved Infected Red Blood Cells in Healthy Thai Adults
Study to Find the Minimum Number of Infective Mosquito Bites Needed to Cause Malaria Infection in Healthy Thai Adults Using Controlled Plasmodium Vivax Mosquito Challenge
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Safety and Reproducibility of a Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a Model to Evaluate Malaria Transmission.
Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01.